Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3).

Tensen CP, Flier J, Van Der Raaij-Helmer EM, Sampat-Sardjoepersad S, Van Der Schors RC, Leurs R, Scheper RJ, Boorsma DM, Willemze R.

J Invest Dermatol. 1999 May;112(5):716-22.

2.

Atopic dermatitis and alpha-chemokines.

Di Bari F.

Clin Ter. 2015;166(3):e182-7. doi: 10.7417/T.2015.1852. Review.

PMID:
26152630
3.

Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands.

Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P.

Front Immunol. 2018 Jan 15;8:1970. doi: 10.3389/fimmu.2017.01970. eCollection 2017. Review.

4.

The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer.

Verbeke H, Geboes K, Van Damme J, Struyf S.

Biochim Biophys Acta. 2012 Jan;1825(1):117-29. doi: 10.1016/j.bbcan.2011.10.008. Epub 2011 Nov 4. Review. Erratum in: Biochim Biophys Acta. 2013 Apr;1835(2):258. Hannelien, Verbeke [corrected to Verbeke, Hannelien]; Karel, Geboes [corrected to Geboes, Karel]; Jo, Van Damme [corrected to Van Damme, Jo]; Sofie, Struyf [corrected to Struyf, Sofie].

PMID:
22079531
5.

Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases.

Altara R, Manca M, Brandão RD, Zeidan A, Booz GW, Zouein FA.

Clin Sci (Lond). 2016 Apr 1;130(7):463-78. doi: 10.1042/CS20150666. Review.

PMID:
26888559
6.

Immunologic mechanisms in psoriasis.

Gottlieb AB.

J Invest Dermatol. 1990 Nov;95(5 Suppl):18S-19S. Review.

7.

An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis".

Wenzel J, Tüting T.

J Invest Dermatol. 2008 Oct;128(10):2392-402. doi: 10.1038/jid.2008.96. Epub 2008 Apr 17. Review.

8.

The Beginning of the End: CXCR3 Signaling in Late-Stage Wound Healing.

Huen AC, Wells A.

Adv Wound Care (New Rochelle). 2012 Dec;1(6):244-248. Review.

9.

Modification of the biological activity of chemokines by dipeptidyl peptidase IV--a side effect in the use of inhibitors?

Mentlein R, Schiemann F, Ludwig A, Brandt E.

Adv Exp Med Biol. 2003;524:37-47. Review. No abstract available.

PMID:
12675221

Supplemental Content

Support Center